3,919 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Destination Wealth Management

Destination Wealth Management acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,919 shares of the biopharmaceutical company’s stock, valued at approximately $362,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. HHM Wealth Advisors LLC lifted its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership acquired a new position in Gilead Sciences during the 4th quarter worth about $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the 4th quarter worth about $29,000. Crews Bank & Trust acquired a new position in Gilead Sciences during the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $117.41 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $118.42. The company has a 50 day moving average of $99.61 and a two-hundred day moving average of $91.39. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market cap of $146.32 billion, a price-to-earnings ratio of 317.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.69%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $17,597,559.49. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 293,356 shares of company stock valued at $29,166,240 over the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. Oppenheimer lifted their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Bank of America increased their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday. Wells Fargo & Company increased their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Royal Bank of Canada increased their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $104.24.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.